Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (61-70 of 143) with videos related to

Pageof 15
Sort By:
Antibody Therapeutics|January 19, 2026
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodiesJingyu Zhan, Mitchell Ho, Lothar Esser, et al.
Hepatology Communications|January 24, 2023
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCCAarti Kolluri, Dan Li, Nan Li, et al.
Mabs|November 4, 2011
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scanSeiji Kawa, Masanori Onda, Mitchell Ho, et al.
The American Journal of Pathology|December 15, 2024
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and ChallengesDan Li, Lalitya Andaloori, Matthew Crowe, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2006
Mesothelin is shed from tumor cellsMitchell Ho, Masanori Onda, Qing-Cheng Wang, et al.
International Journal of Cancer|February 11, 2012
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cellNeetu Kalra, Jingli Zhang, Yunkai Yu, et al.
Immunology|January 14, 2023
Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinomaLin Chen, Siyuan Liu, Dickson Adah, et al.
Antibody Therapeutics|March 14, 2020
Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage displayRuonan Feng, Ruixue Wang, Jessica Hong, et al.
Molecular Therapy Oncolytics|March 23, 2022
A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancerDan Li, Hejiao English, Jessica Hong, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Pageof 15

Showing results (61-70 of 143) with videos related to

Sort By:
Pageof 15
Antibody Therapeutics|January 19, 2026
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodiesJingyu Zhan, Mitchell Ho, Lothar Esser, et al.
Hepatology Communications|January 24, 2023
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCCAarti Kolluri, Dan Li, Nan Li, et al.
Mabs|November 4, 2011
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scanSeiji Kawa, Masanori Onda, Mitchell Ho, et al.
The American Journal of Pathology|December 15, 2024
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and ChallengesDan Li, Lalitya Andaloori, Matthew Crowe, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2006
Mesothelin is shed from tumor cellsMitchell Ho, Masanori Onda, Qing-Cheng Wang, et al.
International Journal of Cancer|February 11, 2012
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cellNeetu Kalra, Jingli Zhang, Yunkai Yu, et al.
Immunology|January 14, 2023
Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinomaLin Chen, Siyuan Liu, Dickson Adah, et al.
Antibody Therapeutics|March 14, 2020
Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage displayRuonan Feng, Ruixue Wang, Jessica Hong, et al.
Molecular Therapy Oncolytics|March 23, 2022
A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancerDan Li, Hejiao English, Jessica Hong, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Pageof 15